Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.51 |
| ▸ | RHEB | Q15382 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | TET3 | O43151 | 1/20 | 0.40 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.40 |
| ▸ | VEGFA | P15692 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | ASPH | Q12797 | 1/20 | 0.40 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.40 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.40 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.40 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.40 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.40 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4309249 | 0.89 | EGLN1 (0.51) | EGLN1CNR2TET3BBOX1VEGFA | |
| SCHEMBL4305872 | 0.86 | EGLN1 (0.47) | EGLN1CNR2MRGPRX4FFAR1FFAR4 | |
| SCHEMBL4309518 | 0.80 | EGLN1 (0.51) | EGLN1RHEBFFAR1TET3BBOX1 | |
| SCHEMBL4311056 | 0.80 | EGLN1 (0.48) | EGLN1CNR2VEGFAFLT1EGLN3 | |
| SCHEMBL13625773 | 0.78 | FAAH (0.51) | EGLN1MRGPRX4FFAR1ROCK2PRKACA | |
| SCHEMBL4303188 | 0.76 | EGLN1 (0.52) | EGLN1CNR2TET3BBOX1VEGFA | |
| SCHEMBL4303435 | 0.76 | EGLN1 (0.65) | EGLN1CNR2VEGFAFLT1EGLN3 | |
| SCHEMBL4319371 | 0.75 | EGLN1 (0.46) | EGLN1FFAR4ALDH1A1ROCK2PRKACA | |
| SCHEMBL17154106 | 0.74 | EGLN1 (0.55) | EGLN1CNR2SMN1; SMN2ALDH1A1ROCK2 | |
| SCHEMBL4313112 | 0.74 | EGLN1 (0.57) | EGLN1EGLN3HIF1ANROCK2PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | US | claimed |
| WO-2009134754-A1 | BENZOIMIDAZOLE GLYCINAMIDES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | WO | claimed |
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | US | disclosed |
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | US | disclosed |
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | US | disclosed |
| WO-2009134754-A1 | BENZOIMIDAZOLE GLYCINAMIDES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134754-A1 | BENZOIMIDAZOLE GLYCINAMIDES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284335-A1 | Benzoimidazoles as prolyl hydroxylase inhibitors | EGLN3, EGLN2, P4HA1 | EGLN1 5/4885RHEB 1692/4885CNR2 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.